Innovative Medication Shows Promise in Managing Resistant Hypertension and Protecting Kidney Function
A new drug, baxdrostat, shows promise in effectively lowering resistant high blood pressure and protecting kidney health, offering hope for a significant advancement in hypertension and kidney disease treatment.
A groundbreaking medication, baxdrostat, has demonstrated significant potential in lowering blood pressure levels that are difficult to control with standard treatments and may also slow the progression of kidney disease. In a recent stage 2 clinical trial involving nearly 200 participants, baxdrostat not only led to a substantial reduction in blood pressure but also showed promising effects on kidney health. Participants treated with baxdrostat exhibited less than half the amount of urinary albumin—a key marker of kidney damage—compared to those receiving traditional care, indicating healthier kidneys.
The research, led by Dr. Jamie Dwyer at the University of Utah Health, highlights the dual benefits of the drug. On average, baxdrostat lowered blood pressure by approximately 8.1 mm Hg more than standard treatments. This is corroborated by a larger, almost 800-patient trial where similar blood pressure reductions were observed, establishing baxdrostat as a potential game-changer in hypertension management.
Unlike conventional medications, baxdrostat operates through a unique mechanism by reducing the production of aldosterone, a hormone that raises blood pressure by increasing salt retention and contributes to kidney inflammation and scarring. Up to a quarter of people with resistant high blood pressure have elevated aldosterone levels, making baxdrostat particularly effective for this demographic.
Given its ability to target the hormone source directly, baxdrostat offers hope not only for better blood pressure control but also for protecting kidney function, especially for the one in seven adults in the U.S. living with chronic kidney disease. Currently, phase III trials are underway to further verify its benefits. The promising results suggest that baxdrostat could revolutionize treatment strategies for resistant hypertension and kidney health, potentially transforming patient outcomes.
Source: https://medicalxpress.com/news/2025-09-drug-lowers-treatment-resistant-high.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Slight Increase in Texas Measles Cases Reaches Over 720
Texas faces a rising measles outbreak with over 720 confirmed cases. Health officials stress vaccination and containment efforts to curb the spread of this highly contagious virus.
Frequent Occurrence of Heart Rhythm Disorder in Long COVID Patients
A groundbreaking study reveals that nearly one-third of long COVID patients, especially middle-aged women, develop POTS, a heart rhythm disorder causing dizziness, fatigue, and impaired quality of life.
Impact of Virtual Maternity Care During COVID-19 on NHS Costs
A study from King's College London reveals that virtual maternity care during COVID-19 increased NHS costs due to more follow-up appointments, highlighting disparities among ethnic groups and underlying long-term trends.
Children with Chronic Health Conditions at Increased Risk of Food Insecurity, New Study Finds
A new study highlights that children with chronic health conditions are at a higher risk of experiencing food insecurity, emphasizing the need for targeted interventions to support vulnerable families.